US CMO Contract Pharmaceuticals (CPL) to close Buffalo plant by the end of 2011 on weak demand it attributes to pharmaceutical industry outsourcing cuts in downturn.
Fine chemicals firm Minakem believes that manufacturing capacity added by its newly acquired API plant in Dunkirk, France will reduce costs and help it compete on a global scale.
AstraZeneca has signed a five year deal with Infosys Technologies for “end-to-end” application maintenance services in areas such as manufacturing, supply chain, finance, human resources and other corporate functions.
AstraZeneca is to cut 1,400 jobs and close more manufacturing facilities by 2013, as it attempts to slim down in preparation for impending generic competition for some of its cornerstone drugs.
Japan’s Shionogi is paying $1.4bn (€959m) for US drugmaker Sciele Pharma as part of a plan to strengthen its sales position in the country’s $286bn a year drug market.
The FDA says that Sandoz, the generics arm of Swiss drug major Novartis, failed to validate manufacturing processes used to produce metoprolol succinate ER tablets at its plant in Wilson, North Carolina.
AstraZeneca and Singapore’s National Cancer Centre (NCCS) have selected inoperable hepatocellular carcinoma (HCC) as the first target for their new drug collaboration.
US software company Conformia hopes that its new web-based drug development suite will help pharmaceutical firms meet with new quality by design (QbD) and risk management guidelines.
Cognizant is gaining ground in the life sciences arena, this week
inking a $95m data management deal with AstraZeneca, just three
months after sealing another multi-million dollar deal with Merck
& Co.
UK-based AstraZeneca has recently given the region's dominant
telecommunications provider, British Telecom (BT) a greater role in
its business, to the tune of £25m.
AstraZeneca has announced a new collaboration with the University
of Texas' MD Anderson Cancer Center as it steps up its reliance on
external partners.
An analyst report released yesterday identified AstraZeneca as
being in 'serious trouble' and branded it as potentially
the 'worst [large cap] performer in [the] entire sector'
over the next eight years.
AstraZeneca's axe has made its latest appearance in South Africa,
with the sale of a packaging plant and the formation of an
outsourcing deal with its new owners.
Kuehne + Nagel (K + N) has inked a new pact with UK-based drug
maker AstraZeneca to provide the global cold chain air and sea
freight for some of its products.
Computer giant IBM has re-inked a huge $1.4bn (€1.0bn) IT
outsourcing deal with drug giant AstraZeneca, who is continuing its
cost-cutting drive to become 'lean and agile'.
AstraZeneca is planning to gradually withdraw from making its own
active pharmaceutical ingredients (APIs) and will use China as the
pinnacle of its new outsourcing plans.
Just weeks after announcing intentions to snap up biologics firm
MedImmune, AstraZeneca has acquired DSM's old biologics
manufacturing facility in Montreal, Canada, a site that's been
gathering dust since it was mothballed...
AstraZeneca has continued to rapidly refocus and bolster its
biologics pipeline through collaboration deals, this time with a
deal for antibody producing technology.
Pharma giant AstraZeneca last week announced its intention to cut
3,000 jobs in an effort to increase productivity and reduce costs.
The company is the latest big pharma to trim its workforce as the
industry readjusts in a more challenging...
Amid 3,000 job cuts, AstraZeneca has invested in hepatitis, obesity
and pulmonary disease drugs as part of a continuing effort to
restructure its business.
Pharmaceutical giant AstraZeneca has invested in a tablet
manufacturing plant in Egypt, which could form a launching pad for
an expansion into emerging markets.
Codexis is using India as a springboard to launch it into direct
sales of high-value generic pharmaceutical intermediates, to be
sold into unregulated markets for use in patented drugs.
AstraZeneca has entered into an agreement with two Contract
Research Organisations (CROs) with the intention of expanding
AstraZeneca's small molecule libraries and enhancing its global
drug discovery offerings.
AstraZeneca will be using Werum's PAS-X system at its two German
production sites to collect operating data from its packaging lines
and define and evaluate key performance indicators (KPI), improving
equipment performance.
In what it claims is the largest investment to date by any
multinational drug company in China, AstraZeneca will spend $100m
(€77.6m) on research and development in the country over the next
three years, targeting primarily the domestic...
A UK university has joined forces with a major pharmaceutical
company in a unique collaboration, worth £2.5 million (€3.6
million) ensuring drug researchers of the future will be trained in
'magic bullet' drug R&D, which...
According to a new report, 2006 will be a crunch year for companies
that have expiring product patents looming. With generics
increasingly penetrating the market, this has thrown into doubt the
growth of this industry in the foreseeable...
AstraZeneca has been fined a hefty €60 million by the European
Commission for manipulating patent laws to keep competitors out of
the market, marking the first occasion that antirust laws have been
used to combat patent abuse.
Pharmaceutical companies are set to face stiff competition, as
generic forms of best-selling biologic drugs will capture a
significant market share. The expiration of drug patents, which
expire within the next few years, opens up...
AstraZeneca has started construction a €30 million tablet
manufacturing plant in Egypt that could form a springboard for an
expansion into emerging markets.
Contract pharmaceutical manufacturer Patheon is to buy Puerto Rican
rival Mova Pharmaceuticals in a transaction that could be valued as
high as $350 million in cash, stock and assumed debt.
AstraZeneca has been hit by the decision of the US Food and Drug
Administration (FDA) not to approve its oral anticoagulant Exanta
(ximelegatran), despite the fact that it is already on the market
in Europe.
The chief executive of leading pharmaceutical company, Astra
Zeneca, has issued a bleak warning to European governments: improve
the business environment, or we'll take our investment elsewhere.
UK company Aerotrim has developed a new line of insulated jackets
for pallets that are currently being trialled by pharmaceutical
companies and other industries, including food manufacturers and
the military.
AstraZeneca has launched new production lines at its production
facility in Dunkerque in northern France, following a 24 per cent
growth in its respiratory sales in 2003. The new lines will produce
aerosol-delivered medicines for...
Israel's Teva has moved a step closer to consolidating its position
as the world's biggest generics manufacturer with the $3.4 billion
(€2.7bn) acquisition of US-based SICOR, which makes active
pharmaceutical ingredients...
A recent trend in drug development has been the re-invigoration of
older pharmaceuticals by developing new versions based on just one
of the two optical isomers of the active compound, a process known
as racemic switching. But critics...
The US market for chiral technologies - used to make single isomers
of compounds - will grow by an estimated 8.8 per cent a year to
reach a value of $1.8 billion (€1.4bn) in 2008, according to
soon-to-be-released market research.
The US Food and Drug Administration (FDA) approved 15 New Molecular
Entities in the current year to 30 September, 2003, setting the
stage to outpace last year's registrations by nearly 20 per cent,
says a report from Cutting...
